Previous Page
Funds CloudBees raises $11.2 million in Series C funding
Name CloudBees
Target
Drive continued revenue growth by rolling out additional product capabilities, fund sales expansion and extend the reach of the CloudBees brand.
Investors
Verizon Ventures, Matrix Partners, LightSpeed Venture Partners and Blue Cloud Ventures.
TARGET The Series C funding brings the total investment in CloudBees
FUND CloudBees, Inc., the Enterprise Platform as a Service (PaaS) innovation leader, has announced that it has closed an $11.2 million Series C financing round.
INVESTORS The round was led by Verizon Ventures, the investment arm of Verizon Communications Inc. The round also included existing investors Matrix Partners and LightSpeed Venture Partners, as well as new investor Blue Cloud Ventures.
to $25.7 million. The new funds will be used to drive continued revenue growth by rolling out additional product capabilities, fund sales expansion and extend the reach of the CloudBees brand.
THE COMPANY CloudBees provides a Continuous Delivery Platform as a Service that accelerates the development, integration and deployment of web and mobile applications. The CloudBees Platform provides a set of services that allow developers to rapidly build and run new business applications and integrate them with other services - all with zero IT administrative overhead.
Abingworth Raises £225m in its Tenth Life Sciences Fund
FUND Abingworth, the international investment group dedicated to life sciences and healthcare, has announced the final closing of its £225m ($375m) fund, Abingworth Bioventures VI (ABV VI). ABV VI, Abingworth’s 10th life sciences fund, exceeded its target of £200 million and invests in life sciences and healthcare both in Europe and the US.
INVESTORS The majority of the funds came from existing investors. We are delighted to have attracted strong support from such high- quality LPs,” said Stephen Bunting, Managing Partner. “This is an exciting time to launch our new fund, deal flow is strong whilst the number of competitors has diminished and markets remain supportive.”
TARGET The fund invests broadly across all stages of development including early and late-stage private deals, VIPEs (Venture Investments in Public Equities), venture growth and public equities. Investment size will range from £5 million to £20 million per investment in total after all rounds of financing.
THE COMPANY Abingworth is an international investment group dedicated exclusively to the life sciences and healthcare sector. Founded in 1973, Abingworth has a lengthy track record of backing market leading companies.
Name Abingworth
Target Investment size will range from £5 million to £20 million per investment in total after all rounds of financing.
Investors Existing Investors.
Pivotal Therapeutics Receives Over CDN $7.7 Million Name Pivotal Therapeutics
Target The funds put us in a strong financial position to execute on our near and longer term growth initiatives towards commercializingVASCAZEN®
Investors
Crossover Healthcare Fund, LLC, Broadfin Capital, LLC and Porter Capital Management Co.
FUND Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies, has announced that it has completed its previously announced debt financing issuing a total of 7,744 units at a price of CDN $1,000 per unit for total proceeds of CDN $7,743,580.
INVESTORS The financing was led by Crossover Healthcare Fund, LLC, and included Broadfin Capital, LLC and Porter Capital Management Co.
TARGET Mrs. Rachelle MacSweeney, President and COO stated “The funds put us in a strong financial position to execute
on our near and longer term growth initiatives towards commercializingVASCAZEN®. We look forward to working with our new financial partners to build value at Pivotal.”
THE COMPANY Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CSE: PVO) specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics’ lead product VASCAZEN® is a prescription only Medical Food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications.